TY - JOUR
T1 - Evaluation of chronic urticaria in patients with hashimoto thyroiditis
AU - Kandeel, Ala Addin
AU - Zeid, Mohamed
AU - Helm, Thomas
AU - Lillie, Madeline A.
AU - Donahue, Eileen
AU - Ambrus, Julian L.
N1 - Funding Information:
The authors would like to thank Drs. Jeffrey Rock-off, Christine Holland, and Michel Akl for referring patients. They would like to thank Professor Dieter Maurer for advice, Dr. Franz Kricek, Novartis, for providing recombinant FceRI, Dr. Allen Kaplan, University of South Carolina, for providing control sera, and Natalie Brock for administrative assistance. Technical assistance was provided by Judy Horn, Department of Pathology, Buffalo General Hospital. Thyroid samples were provided by Dr. Janet Winston, Department of Pathology, Roswell Park Cancer Institute. This work was funded through the Systemic Autoim-
PY - 2001
Y1 - 2001
N2 - The coincidence of Hashimoto thyroiditis (HT) and chronic idiopathic urticaria (CIU) is a commonly observed phenomenon in western New York. Previous literature suggested that there may be a direct relationship between them. We undertook these studies to determine whether humoral or cell-mediated mechanisms might link HT and CIU. Skin biopsies from patients with CIU, with or without HT, were indistinguishable by light microscopy. No immune complex deposition was observed, although only the skin from patients with CIU and HT contained perivascular fibrin deposits. Similarly, immunohistochemical studies evaluating cellular expression of CD3, CD4, CD8, CD20, and CD68 failed to differentiate between CIU with or without HT. Analysis of Vβ restriction in thyroid tissue of patients with HT and the skin of patients with CIU and HT by in situ polymerase chain reaction failed to reveal any oligoclonal T-lymphocyte subpopulations. In contrast, only patients with CIU and HT had anti-FcεRI antibodies in their sera that could induce degranulation of normal basophils. Some sera from patients with CIU and HT caused degranulation of normal basophils in the absence of anti-FceRI. The factor causing basophil degranulation in these sera was not determined. Patients with CIU and HT failed to improve clinically with thyroid replacement therapy. All CIU patients were equally well managed with symptomatic therapies. In conclusion, HT likely represents a marker of other autoimmunity, rather than being a direct causative agent in CIU. Management of CIU, with or without HT and with or without anti-FceRI antibodies, should be the same. Future studies will have to examine whether cell-mediated responses participate in CIU, especially in association with HT.
AB - The coincidence of Hashimoto thyroiditis (HT) and chronic idiopathic urticaria (CIU) is a commonly observed phenomenon in western New York. Previous literature suggested that there may be a direct relationship between them. We undertook these studies to determine whether humoral or cell-mediated mechanisms might link HT and CIU. Skin biopsies from patients with CIU, with or without HT, were indistinguishable by light microscopy. No immune complex deposition was observed, although only the skin from patients with CIU and HT contained perivascular fibrin deposits. Similarly, immunohistochemical studies evaluating cellular expression of CD3, CD4, CD8, CD20, and CD68 failed to differentiate between CIU with or without HT. Analysis of Vβ restriction in thyroid tissue of patients with HT and the skin of patients with CIU and HT by in situ polymerase chain reaction failed to reveal any oligoclonal T-lymphocyte subpopulations. In contrast, only patients with CIU and HT had anti-FcεRI antibodies in their sera that could induce degranulation of normal basophils. Some sera from patients with CIU and HT caused degranulation of normal basophils in the absence of anti-FceRI. The factor causing basophil degranulation in these sera was not determined. Patients with CIU and HT failed to improve clinically with thyroid replacement therapy. All CIU patients were equally well managed with symptomatic therapies. In conclusion, HT likely represents a marker of other autoimmunity, rather than being a direct causative agent in CIU. Management of CIU, with or without HT and with or without anti-FceRI antibodies, should be the same. Future studies will have to examine whether cell-mediated responses participate in CIU, especially in association with HT.
UR - http://www.scopus.com/inward/record.url?scp=0034765583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034765583&partnerID=8YFLogxK
U2 - 10.1023/A:1012288602962
DO - 10.1023/A:1012288602962
M3 - Article
C2 - 11720006
AN - SCOPUS:0034765583
SN - 0271-9142
VL - 21
SP - 335
EP - 347
JO - Journal of Clinical Immunology
JF - Journal of Clinical Immunology
IS - 5
ER -